News | March 20, 2009

Phase 3 Data from Genetically Targeted Beta Blocker for Chronic Heart Failure Presented at ACC

March 20, 2009 - ARCA biopharma Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, said today two Gencaro (bucindolol hydrochloride) abstracts will be presented as poster sessions at the American College of Cardiology 58th Annual Scientific Session March 29-31, 2009 in Orlando, FL.

The abstracts present data from the pivotal Phase 3 BEST trial of Gencaro in patients with advanced chronic heart failure. Poster 170 is “All-Cause Mortality Endpoint Comparison in Large Beta-Blocker Heart Failure Trials: U.S. Versus Rest of World.” Christopher O’Connor, M.D., professor of medicine in the division of cardiology, chief of the division of clinical pharmacology in the department of medicine, and director of the Duke heart failure program at Duke University Medical Center, is scheduled to present a comparative analysis of U.S. versus ROW primary and other clinical endpoint data from the “MERIT,” “COPERNICUS,” and “BEST” trials in a poster presentation (ACC Poster Contributions 1024 – Myocardial Function/Heart Failure – Clinical Pharmacology) on Sunday, March 29, from 3:30 p.m. to 4:30 p.m. (eastern).

Poster 184 is “Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindolol in Moderate to Severe HF Patients, According to Prespecified Statistical Analysis Plan.” Michael Bristow, M.D., ARCA’s founder and chief science and medical officer, is scheduled to present unpublished results of the pivotal Phase 3 BEST trial of Gencaro in patients with advanced chronic heart failure analyzed according to the pre-specified regulatory statistical analysis plan in a poster presentation (ACC Poster Contributions 1024 – Myocardial Function/Heart Failure – Clinical Pharmacology) on Sunday, March 29, 2009, from 3:30 p.m. to 4:30 p.m. (eastern).

Dr. Bristow will also participate in two panel discussions. “Pharmacogenomics and the Failing Heart.” ACC Symposium 604 – The Role of Genetic Testing in the Diagnosis and Management of Heart Failure will be held Sunday, March 29 from 10:30 a.m. to noon (eastern). The second discussion is ACC Meet the Experts 211 – Hemodynamic Monitoring in Implanted Arrhythmia Devices, Monday, March 30, from 11 a.m. to noon (eastern).

ARCA biopharma's lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. The new drug application for approval of Gencaro for the indication of chronic heart failure, including the proposed brand name, is currently under review by the FDA with a Prescription Drug User Fee Act (PDUFA) date of May 31, 2009. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. The company’s second compound in development, NU172, is a direct thrombin inhibitor, which has completed Phase 1b development for use as a potential short-acting anticoagulant during medical or surgical procedures.

For more information: www.arcabiopharma.com

Related Content

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

News | Pharmaceuticals | January 09, 2020
January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies,
 Christie Ballantyne

Dr. Christie Ballantyne, professor of medicine and chief of the section of cardiology at Baylor College of Medicine

News | Pharmaceuticals | December 30, 2019
December 30, 2019 — A drug therapy targeting the production of a protein produced by the liver has led to sustained a
Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | December 16, 2019 | Dave Fornell, Editor
The U.S. Food and Drug Administration (FDA) approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive...
Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019
July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can sig
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Overlay Init